Merck has discontinued Recarbrio, an intravenous antibiotic combination approved in 2019 for multidrug-resistant gram-negative infections. The drug combines imipenem, cilastatin, and relebactam to counter resistance mechanisms like KPC enzymes found in carbapenem-resistant Enterobacterales. Originally indicated for complicated urinary tract infections, intra-abdominal infections, and hospital-acquired pneumonia, Recarbrio's label expanded to children in 2025. Merck cited an ongoing portfolio review unrelated to safety or quality concerns. Infectious disease specialists acknowledge an immediate though narrow clinical gap, particularly for patients with difficult-to-treat Pseudomonas aeruginosa infections. The discontinuation highlights vulnerabilities in the antibiotic market's payment model for reserved drugs. Experts point to the PASTEUR Act's subscription-style purchasing proposal as a potential solution to sustain antibiotic development and availability, emphasizing that unsustainable economics—rather than clinical inadequacy—drove the withdrawal.

The Centers for Medicare and Medicaid Services announced that all state Medicaid programs, plus the District of Columbia and Puerto Rico, have applied to participate in GENEROUS, a five-year voluntary model launched in January 2026. The initiative aims to control escalating Medicaid drug costs through CMS-facilitated negotiations between manufacturers and state agencies, with manufacturers providing supplemental rebates to align Medicaid prices with international benchmarks. With Medicaid net drug spending reaching $60 billion in 2024—a $10 billion increase from 2022—the model addresses unsustainable cost growth while building on existing programs like the Medicaid Drug Rebate Program and the Cell and Gene Therapy Access Model. Under GENEROUS, participating manufacturers offer lower drug prices based on international reference pricing in exchange for standardized coverage criteria across all participating states. The model is voluntary for both manufacturers and states, with applications finalized by September 30, 2026. By leveraging international pricing data, GENEROUS enables state Medicaid programs to negotiate lower drug costs while ensuring broader patient access to life-saving medications and providing manufacturers with expanded market opportunities through streamlined coverage requirements.

Researchers at University College London and the University of Cambridge have developed personalized computational models of triple-negative breast cancer (TNBC) using patient genomic data to create tumor "digital twins" that predict treatment responses and identify targeted therapies to overcome drug resistance. Published in Cell Reports Medicine, the study employed symbolic artificial intelligence—an approach based on logical rules and biological interactions rather than statistical pattern recognition—to generate interpretable predictions. Using genomic data from 31 patients in the PARTNER clinical trial, which evaluated combination chemotherapy with or without the PARP inhibitor olaparib, the models correctly predicted treatment responses in 74% of cases. For 10 of 13 patients with incomplete treatment responses, the models predicted that adding targeted therapy could achieve pathological complete response. ATM inhibition emerged as the most promising strategy, particularly for tumors with genetic alterations associated with increased DNA replication stress. Since TNBC accounts for approximately 15% of breast cancers and lacks receptors targeted by conventional drugs, this personalized modeling approach offers significant potential to optimize treatment selection and improve outcomes in this difficult-to-treat cancer subtype.

This research evaluates the cost-effectiveness of combining ribociclib, a cyclin-dependent kinase 4/6 inhibitor, with aromatase inhibitors compared to aromatase inhibitor monotherapy for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer in pre- and postmenopausal women with stage II and III disease. Conducted from a Canadian payer perspective, the analysis assesses the economic implications of adding ribociclib to standard endocrine therapy in this patient population. The study addresses a critical healthcare decision point regarding whether the clinical benefits of combination therapy justify additional treatment costs within Canada's healthcare system. By examining incremental cost-effectiveness ratios and quality-adjusted life years, this research provides evidence to guide resource allocation and formulary decisions for early breast cancer management, informing both clinicians and policymakers about the value proposition of CDK4/6 inhibitor-based adjuvant strategies in Canada's healthcare context.

Researchers at Stanford University and collaborating institutions have developed a comprehensive framework for digital biomarkers to advance the diagnosis and monitoring of neurodegenerative diseases. Published in Nature Reviews Bioengineering, this work addresses the critical need for objective, non-invasive measurement tools that can detect disease progression earlier than traditional clinical assessments. The framework integrates multiple technological approaches including wearable sensors, smartphone-based applications, and artificial intelligence algorithms to capture behavioral, motor, and cognitive changes characteristic of conditions like Alzheimer's disease, Parkinson's disease, and ALS. These digital biomarkers leverage machine learning to identify subtle patterns in gait, voice, tremor, and cognitive performance that correlate with neurodegeneration. The significance of this work lies in its potential to enable earlier diagnosis, facilitate more precise patient stratification for clinical trials, and support real-world monitoring of therapeutic interventions. By combining rigorous validation methodologies with practical implementation strategies, the framework establishes a blueprint for translating digital health technologies into clinically actionable tools that could substantially improve outcomes in neurodegenerative disease management.

Nepal's sixth national prevalence drug-resistant tuberculosis survey, published in October 2024 in Infectious Diseases of Poverty, provides critical epidemiological data on the burden of drug-resistant TB in the country. This open-access research represents the latest comprehensive assessment of drug-resistant tuberculosis prevalence across Nepal's population, building on previous national surveys to track trends over time. The study examines the extent of resistance to first-line and second-line anti-tuberculosis medications, offering essential information for understanding disease patterns and treatment challenges. By documenting current prevalence figures, the survey identifies the scale of drug-resistant TB as a public health concern in Nepal and informs strategic responses to combat the disease. The findings are significant for policymakers and healthcare professionals, as drug-resistant tuberculosis poses substantial challenges to TB control programs, requiring more complex and costly treatment regimens. This prevalence data enables Nepal's health authorities to allocate resources effectively, strengthen surveillance systems, and implement targeted interventions to address drug-resistant TB and improve patient outcomes.

Advances in CRISPR gene editing and stem cell-derived embryo models offer significant biomedical promise, but approved therapies command extraordinary costs, ranging from $2.2 million for Casgevy to $4.25 million for Lenmeldy, raising critical questions about equitable access. This article addresses how affordability, accessibility, ethical compliance, and distributive inequality can be measured through a single coherent index to inform policy decisions. The authors audited an existing Genomic Equity Accessibility Framework (GEAF) and identified fundamental mathematical flaws, including dimensional incompatibility and unbounded outputs. They reconstructed GEAF' as a normalized, bounded (0–100) weighted composite incorporating six dimensionless components—accessibility, ethical compliance, affordability, equity, policy strength, and research efficiency—using multi-attribute utility theory. Testing across seven scenarios anchored to actual list-price data revealed GEAF' ranging from 27.9 to 86.5, with cost and inequality factors identified as primary drivers. Monte Carlo sensitivity analysis demonstrated no overlap between baseline and equity-intervention scenarios, establishing GEAF' as a mathematically rigorous tool for evaluating genomic therapy distribution policies and supporting evidence-based decision-making.

The CGTS 2026 conference, co-chaired by Burt Zweigenhaft, PhD, DLitt, of AVBCC, opens registration with a comprehensive agenda addressing critical challenges in cell and gene therapy. The event begins with McKesson and InspiroGene's 2026 State of the Industry Report, presented by Joe DePinto, Head of Cell and Gene Advanced Therapies, offering insights into industry opportunities and obstacles. A fireside chat featuring industry leaders including Nicole Verdun from Verdun Advisors and Madan Jagasia, MD, CEO of Obsidian Therapeutics, moderated by Marc Samuels of ADVI Health, examines pressing issues such as supply chain dynamics, manufacturing challenges, and expanding care into community settings. A pivotal panel discussion, moderated by Scott Wallace, MD, JD, explores the fundamental economic tension when transformative therapies arrive before robust business models exist. Panelists including Lesli Marasco and Will Shrank, former CMO of Humana and CEO of Aradigm, address how payers, employers, and providers can recognize long-term value while managing near-term budgetary pressures. Additional sessions tackle translating scientific promise into real-world product effectiveness, underscoring the industry's evolution beyond laboratory success toward practical clinical and commercial viability.

Blood tests are revolutionizing Alzheimer's disease diagnosis, transforming a historically complex, time-consuming process into a simple, accessible screening tool. Traditionally, diagnosis required cognitive examinations combined with invasive and expensive procedures such as cerebrospinal fluid analysis via lumbar puncture or PET brain imaging to detect tau tangles and amyloid plaques. These barriers contributed to approximately 75% of dementia cases remaining undiagnosed globally. Advanced blood testing technologies now detect the same biomarkers—tau and amyloid proteins—that clinicians previously sought through invasive procedures, eliminating months of waiting and uncertainty. This shift enables faster diagnosis without unnecessary lumbar punctures or PET scans in many cases, allowing patients and families to transition from limbo to actionable planning regarding treatment options, care arrangements, and future preparations. For clinicians, the increased accessibility of blood-based biomarkers promises earlier intervention opportunities and better resource allocation in primary care settings, fundamentally improving diagnostic equity and patient outcomes across diverse populations.

Two groundbreaking gene therapies, Casgevy and Lyfgenia, are transforming treatment options for sickle cell disease by potentially eliminating severe pain crises in eligible patients. However, significant barriers threaten widespread adoption. High treatment costs, complex procedural requirements, and a shortage of sickle cell specialists have limited patient access to these therapies. Beyond individual treatment availability, experts identify critical gaps in the broader sickle cell care infrastructure, revealing that current healthcare systems are inadequately equipped to support comprehensive patient management. These challenges have prompted coordinated efforts to establish more robust treatment networks across the nation, ensuring patients can access both the innovative gene therapies and the specialized medical support necessary for optimal outcomes. Addressing these systemic issues is essential to translating scientific breakthroughs into tangible health improvements for sickle cell disease patients.

Antisense oligonucleotides, or ASOs, are synthetic DNA-like strands designed to bind specific RNA molecules and suppress disease-causing protein production. A new open-access review in Molecular Biology Reports by Abhigna Nagaraj and colleagues at JSS Academy of Higher Education and Research examines the computational toolkit revolutionizing ASO engineering, from sequence selection through three-dimensional structural prediction, molecular docking, and molecular dynamics simulation. ASOs offer distinct advantages over conventional small-molecule drugs and monoclonal antibodies due to their programmability—researchers can design molecules targeting virtually any RNA sequence with high specificity and reproducible manufacturing. Unlike small molecules requiring protein surface pockets, ASOs target RNA directly, enabling treatment of previously undruggable diseases. The field has evolved through multiple generations of chemical modifications to enhance stability and cellular uptake. First-generation phosphorothioate backbones replaced non-bridging oxygen with sulfur for nuclease resistance; second-generation chemistry added 2'-O-methyl or 2'-O-methoxyethyl modifications and chimeric gapmer designs; third-generation chemistries include locked nucleic acids. With multiple approved drugs and dozens in clinical trials, ASOs represent a leading precision medicine platform for personalized therapies, particularly benefiting rare genetic disorders lacking alternative treatments.

Neoantigen cancer vaccines represent a transformative personalized medicine approach, with artificial intelligence playing a crucial role in identifying which tumor mutations to target. In August 2026, Merck and Moderna announced that their personalized mRNA neoantigen vaccine successfully met both primary endpoints in a phase 3 melanoma trial involving over one thousand patients, marking the first neoantigen vaccine to clear phase 3 testing. The treatment workflow involves sequencing individual tumors, using AI models to rank thousands of candidate mutations, and manufacturing patient-specific vaccines. However, despite high benchmark performance scores, prediction models demonstrate significant limitations in clinical practice. While leading classifiers like NetMHCpan-4.0-L and MHCflurry-L report area-under-curve scores exceeding 0.97, published experimental data reveals that only 53 of 1,948 predicted peptide-MHC combinations successfully triggered measurable T-cell responses. This discrepancy between laboratory predictions and clinical outcomes highlights both the promise and remaining challenges in neoantigen vaccine development, establishing a new paradigm for precision oncology while revealing where predictive algorithms still require refinement.

Recent advances in antituberculosis drug development demonstrate significant progress in translating mechanistic discoveries into clinical applications. This comprehensive review, published in Molecular Biomedicine in October 2026, examines emerging therapeutic strategies and molecular innovations targeting tuberculosis treatment. The analysis bridges fundamental research breakthroughs with practical clinical implementations, addressing the urgent need for improved antituberculosis agents. As drug-resistant tuberculosis strains continue to challenge global public health efforts, these advances represent critical developments in enhancing treatment efficacy and patient outcomes. The review synthesizes current knowledge on novel drug mechanisms, therapeutic approaches, and their clinical translation pathways. By connecting mechanistic understanding with real-world medical applications, this work provides essential insights for researchers, clinicians, and pharmaceutical developers working to combat tuberculosis. The research underscores the importance of continued innovation in antituberculosis therapeutics to address emerging resistance patterns and improve disease management strategies worldwide.

Roche announced that detailed results from the evERA Breast Cancer study, published in The New England Journal of Medicine, demonstrated that its investigational giredestrant—an oral selective oestrogen receptor degrader (SERD)—combined with everolimus significantly improved progression-free survival (PFS) in patients with oestrogen receptor-positive advanced breast cancer who experienced disease progression after CDK4/6 inhibitor and endocrine therapy treatment. In the ESR1-mutated population, median PFS reached 10.0 months with the giredestrant combination versus 5.5 months with standard therapy, representing a 62 percent risk reduction. In the broader intent-to-treat population, median PFS was 8.8 months compared with 5.5 months, with a 44 percent risk reduction. Overall survival data showed a positive trend, though remained immature at analysis. The combination demonstrated a manageable safety profile consistent with individual component medications, with no unexpected adverse events, no photopsia cases, and low bradycardia rates. This all-oral treatment option addresses the critical clinical need for additional therapies to combat endocrine therapy resistance in advanced breast cancer patients.

Gene therapies Casgevy and Lygfenia represent significant advances for sickle cell disease patients, now approved for severe forms of the disease in patients as young as two years old. These CRISPR-based therapies can substantially reduce pain crises, as demonstrated by improved patient outcomes, with an estimated 25 to 35 percent of the sickle cell population meeting current clinical criteria for treatment. However, significant barriers to access remain. Treatment duration spans up to one year and can cause permanent infertility, while costs range from $2.2 to $3.1 million per course, excluding additional healthcare expenses. These factors have prompted intervention efforts, notably the Centers for Medicare and Medicaid Services' Cell and Gene Therapy Access Model, launched in 2024. This program works with 32 states, the District of Columbia, and Puerto Rico to establish outcome-based pricing agreements with manufacturers, aiming to address disparities between privately insured patients and the majority of sickle cell patients covered by Medicaid or the Children's Health Insurance Program. Expanding equitable access to these transformative therapies remains critical.

Nearly a decade after chimeric antigen receptor (CAR) T-cell therapies entered the market, Medicare lacks a sustainable payment framework for cell and gene therapies (CGTs), according to policy experts Dan Farmer and Remy Brim speaking at the National Association of Specialty Pharmacy's annual meeting. Currently, Medicare reimburses hospitals for most CGTs through a single lump-sum diagnosis-related group (DRG) payment, the same mechanism used for standard inpatient stays. While new products receive temporary add-on payments covering 50-65% of costs, this support expires within two years, forcing hospitals to absorb remaining expenses within flat DRG rates. Rather than creating dedicated codes for new therapies, CMS has considered consolidating additional immunotherapies into the existing CAR T-specific DRG 018, raising concerns about payment accuracy dilution. Meanwhile, Medicaid has implemented a more proactive Cell and Gene Therapy Access Model, negotiating pricing discounts and outcomes-based rebates directly with manufacturers. Thirty-three states and DC opted into this model for sickle cell gene therapies, covering approximately 84% of Medicaid enrollees. The persistent payment ambiguity is creating investment risk, as commercial insurers increasingly exclude CGTs from coverage.

The cell and gene therapy manufacturing sector is experiencing significant transformation as companies navigate scaling challenges and regulatory evolution. The FDA has adopted a more flexible approach to overseeing cell and gene therapy manufacturing, reflecting the industry's growing maturity. Major developments include substantial investments and facility expansions, with GSK committing $800 million for a new Pennsylvania R&D and manufacturing hub, Bayer unveiling a $2.2 billion Ohio manufacturing site, and Virginia securing $12.6 billion in onshoring projects. Meanwhile, the sector faces consolidation pressures, exemplified by AmplifyBio's closure due to funding scarcity and Caribou's decision to exit due to financing struggles. Notable acquisitions include a CDMO acquiring Landmark Bio and Multiply Labs securing $75 million in funding. The industry also witnessed FDA delays for Novo's hemophilia A drug review citing factory issues, underscoring manufacturing's critical role in therapy approval. These developments reflect the sector's transition toward sustainable, scalable infrastructure essential for commercializing advanced therapies and meeting growing global demand.

Micro-RNAs (miRNAs) are increasingly recognized as clinically actionable biomarkers across solid and hematologic cancers, functioning as state reporters of critical cancer hallmarks including PI3K/AKT survival signaling, p53 checkpoint loss, MYC-driven proliferation, epithelial-to-mesenchymal transition plasticity, hypoxia adaptation, and immune escape mechanisms. This comprehensive analysis establishes a pan-cancer framework centered on high-centrality miRNA nodes frequently observed in cancer biology and liquid biopsies, including miR-21, the miR-34 family, the miR-17~92 cluster, let-7 family, miR-200 family, miR-210, miR-155, and miR-221/222. The framework expands to include clinically relevant modules such as miR-126 in angiogenesis, miR-16/15 apoptosis checkpoints, miR-29 epigenetic remodeling, miR-146a inflammatory regulation, miR-122 metabolism, and miR-10b/miR-9 in cancer stem cell plasticity. These miRNA modules are translated across therapeutic contexts—chemotherapy, targeted therapy, endocrine therapy, radiotherapy, and immunotherapy—elucidating mechanisms of response, resistance, and escape. The integrated mapping to clinical applications spans early detection, tumor characterization, prognosis assessment, treatment monitoring, and early resistance detection, providing clinicians with guidance on miRNA biomarker validation strength and clinical utility.

This comprehensive review examines recent advances in treating Triple-Negative Breast Cancer (TNBC), an aggressive malignancy with historically limited therapeutic options. The article provides an in-depth analysis of emerging targeted therapies and immunotherapies designed to improve patient outcomes. Within targeted approaches, the authors evaluate PARP inhibitors, EGFR inhibitors, and PI3K inhibitors, integrating evidence from clinical trials and analyzing their efficacy across molecular subtypes. The immunotherapy landscape encompasses immune checkpoint inhibitors, Chimeric Antigen Receptor (CAR) T-cell therapy, and vaccine-based approaches. The review critically assesses combination strategies, examining clinical efficacy, safety profiles, and resistance mechanisms. Additionally, it highlights innovative emerging therapeutic modalities including bispecific antibodies, advanced drug delivery systems, and personalized medicine approaches. The article addresses critical challenges in TNBC management, particularly therapy resistance and biomarker-driven treatment selection. This work is significant for oncologists and researchers as it synthesizes current knowledge on transformative treatment strategies that may substantially enhance survival rates and quality of life for TNBC patients, who historically face poor prognoses compared to other breast cancer subtypes.

# Professional Summary This article, published in Molecular Cancer, examines precision nanomedicine as a strategy to overcome barriers in cancer immunotherapy and targeted drug delivery by navigating the complex tumor microenvironment. Led by Hussein Sabit, Timothy M. Pawlik, and colleagues, the research addresses how nanoparticles can be engineered to penetrate hostile tumor tissue and enhance therapeutic efficacy. The tumor microenvironment presents significant challenges to conventional cancer treatments, including immunosuppressive factors, physical barriers, and poor drug penetration. The authors explore how nanomedicine platforms can be optimized to deliver immunotherapeutic agents and targeted drugs more effectively while minimizing systemic toxicity. By integrating nanotechnology with immunotherapy, this approach aims to improve treatment outcomes and overcome drug resistance. The work is particularly relevant for precision oncology, as it demonstrates how tailored nanomedicines can be designed to interact favorably with the tumor microenvironment rather than being hindered by it, potentially revolutionizing how cancer patients receive targeted therapeutic interventions.